Overview
Principal investigator
Eligibility criteria
Inclusion Criteria:
* Diagnosis of follicular lymphoma (FL).
* Have CD20+, histologically confirmed classic FL (previously Grade 1 to 3a FL) at most recent representative tumor biopsy based on the local pathology report, according to the 5th edition of World Health Organization (WHO) Classification of Haematolymphoid Tumours.
* Are willing and able to comply with procedures required in the protocol.
* Must have stage, III, IV or II with bulky disease \>= 7cm).
* Must be in need of systemic treatment per investigator, as evidenced by meeting at least one of the Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.
* Has one or more target lesions:
* A positron emission tomography (PET)/computerized tomography (CT) scan demonstrating PET-positive lesion(s), and
* \>=1 measurable nodal lesion (long axis \>1.5cm) or \>=1 measurable extra-nodal lesion (long axis \>1.0 cm) on CT scan or MRI
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
* Able to receive at least one of the standard of care chemoimmunotherapy (CIT) treatment regimens: \[Arm B\] at the discretion of the Investigator, and rituximab and lenalidomide (R2) \[Arm C\].
* Have laboratory values meeting the criteria in the protocol.
Exclusion Criteria:
* Had major surgery within 4 weeks prior to randomization.
* Have active cytomegalovirus (CMV) disease.
* Diagnosis of follicular lymphoma (FL).
* Have CD20+, histologically confirmed classic FL (previously Grade 1 to 3a FL) at most recent representative tumor biopsy based on the local pathology report, according to the 5th edition of World Health Organization (WHO) Classification of Haematolymphoid Tumours.
* Are willing and able to comply with procedures required in the protocol.
* Must have stage, III, IV or II with bulky disease \>= 7cm).
* Must be in need of systemic treatment per investigator, as evidenced by meeting at least one of the Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.
* Has one or more target lesions:
* A positron emission tomography (PET)/computerized tomography (CT) scan demonstrating PET-positive lesion(s), and
* \>=1 measurable nodal lesion (long axis \>1.5cm) or \>=1 measurable extra-nodal lesion (long axis \>1.0 cm) on CT scan or MRI
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
* Able to receive at least one of the standard of care chemoimmunotherapy (CIT) treatment regimens: \[Arm B\] at the discretion of the Investigator, and rituximab and lenalidomide (R2) \[Arm C\].
* Have laboratory values meeting the criteria in the protocol.
Exclusion Criteria:
* Had major surgery within 4 weeks prior to randomization.
* Have active cytomegalovirus (CMV) disease.
For Referring Providers
Do you have a patient you think would be a good candidate for this trial? Learn more about enrolling your patient.